Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 8/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4826666 | 1.00 | RAB9A (0.37) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6599032 | 0.80 | SMN1; SMN2 (0.42) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6599035 | 0.80 | SMN1; SMN2 (0.42) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL4825098 | 0.76 | ALDH1A1 (0.37) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL4825102 | 0.76 | ALDH1A1 (0.37) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL3554224 | 0.72 | HTT (0.40) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL3554226 | 0.72 | HTT (0.40) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL1684439 | 0.68 | ALDH1A1 (0.55) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL1684435 | 0.68 | ALDH1A1 (0.55) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL18776600 | 0.67 | HTT (0.40) | RAB9AALDH1A1KMT2ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446105-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-11-04 | — | — | US | disclosed |
| US-20050119291-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
| EP-1485374-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076433-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119291-A1 | Pyrimidine compounds | TYMP, TYMS, CCNT1 | RAB9A 3499/4885ALDH1A1 713/4885KMT2A 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.